Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference
28 déc. 2023 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic...
Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers
05 déc. 2023 07h00 HE
|
Replimune Group Inc
RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not...
Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research
08 nov. 2023 09h10 HE
|
Replimune Group Inc
WOBURN, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic...
Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update
07 nov. 2023 08h00 HE
|
Replimune Group Inc
The Company plans to hold a conference call in early December to provide a comprehensive RP1 skin cancer program update including: Topline data from the CERPASS clinical trial of RP1 combined...
Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
03 nov. 2023 19h30 HE
|
Replimune Group Inc
WOBURN, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic...
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
19 sept. 2023 16h01 HE
|
Replimune Group Inc
WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic...
Replimune Announces Appointment of Emily Hill as Chief Financial Officer
19 sept. 2023 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic...
Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update
03 août 2023 08h00 HE
|
Replimune Group Inc
Topline data from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma expected in early Q4 2023 and Biologics License...
Replimune to Present at Two Upcoming Investor Conferences
01 août 2023 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed...
Replimune Announces Sander Slootweg will Depart from its Board of Directors
20 juil. 2023 08h00 HE
|
Replimune Group Inc
WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic...